Rhc80267

CB1R agonists WIN55,212,2 (WIN), CP55,940 (CP) and 2-arachydonoylglycerol (2-AG), CB1R inverse agonist AM281 (AM) and DAGL inhibitor RHC80267 (RHC) were obtained from R&D Systems Europe. Dimethyl Sulfoxide (DMSO), Tetrahydrolipstatin (THL), Δ⁹-Tetrahydrocannabinol solution (THC), Pertussis Toxin (PTX), Forskolin (Fsk), monoclonal mouse anti-Tau antibody, monoclonal mouse anti-microtubule-associated protein 2 (anti-MAP2) antibody, Bovine Serum Albumin (BSA) and Poly-D-Lysine were obtained from SIGMA-ALDRICH. Polyclonal anti-DAGLα antibody was obtained from Frontier Institute co., ltd (JAPAN). B27, Lipofectamine 2000 and Neurobasal were obtained from Life Technologies.
AKAR4, Lyn-AKAR4 and AKAR4-Kras probes were provided by Dr. Jin Zhang's laboratory (Baltimore, USA). ^TEpac^VV probe provided by Dr. Kees Jalink laboratory (Amsterdam, Netherlands).

The following chemicals were products of R&D Systems: AVP, TTX, kynurenic acid, picrotoxin, SR49059, U73122, heparin, thapsigargin, bisindolylmaleimide II (Bis II), RHC 80267, and ML 133. Glibenclamide was purchased from MedChemExpress. diC8-PIP₂ was purchased from Echelon Biosciences. Drugs were initially prepared in stock solution, aliquoted, and stored at −20°C. For those chemicals requiring dimethylsulfoxide (DMSO) as a solvent, the concentration of DMSO was <0.1%.